Inside informationFrench
Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 23/01/2026, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- French
- AMF reference
- 130718_20260123